BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Guinet-Charpentier C, Champigneulle J, Williet N, Peyrin-Biroulet L, Morali A. The association of autoimmune diseases with pediatric ulcerative colitis does not influence its disease course. Scand J Gastroenterol 2016;51:33-40. [PMID: 26152794 DOI: 10.3109/00365521.2015.1058415] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
Number Citing Articles
1 Chien MM, Chang MH, Chang KC, Chiu YC, Chen HL, Hsu HY, Wu JF. The characteristics of pediatric ulcerative colitis with primary sclerosing cholangitis: A single-center study in Taiwan. Pediatr Neonatol 2021;62:483-90. [PMID: 34074613 DOI: 10.1016/j.pedneo.2021.05.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Attauabi M, Zhao M, Bendtsen F, Burisch J. Systematic Review with Meta-analysis: The Impact of Co-occurring Immune-mediated Inflammatory Diseases on the Disease Course of Inflammatory Bowel Diseases. Inflammatory Bowel Diseases 2021;27:927-39. [DOI: 10.1093/ibd/izaa167] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
3 García MJ, Pascual M, Del Pozo C, Díaz-González A, Castro B, Rasines L, Crespo J, Rivero M. Impact of immune-mediated diseases in inflammatory bowel disease and implications in therapeutic approach. Sci Rep 2020;10:10731. [PMID: 32612137 DOI: 10.1038/s41598-020-67710-2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
4 Zhong Y, Yan F, Jie W, Zhou Y, Fang F. Correlation between serum homocysteine level and ulcerative colitis: A meta-analysis. Pteridines 2019;30:114-20. [DOI: 10.1515/pteridines-2019-0013] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
5 Park S, Kim TJ, Lee JY, Kim ER, Hong SN, Chang DK, Yang M, Kim S, Shin M, Kim Y. Comorbid immune-mediated diseases in inflammatory bowel disease: a nation-wide population-based study. Aliment Pharmacol Ther 2019;49:165-72. [DOI: 10.1111/apt.15076] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 3.5] [Reference Citation Analysis]
6 Shiau H, Ihekweazu FD, Amin M, Fofanova T, Miloh T, Kellermayer R. Unique Inflammatory Bowel Disease Phenotype of Pediatric Primary Sclerosing Cholangitis: A Single-Center Study. J Pediatr Gastroenterol Nutr. 2017;65:404-409. [PMID: 28141677 DOI: 10.1097/mpg.0000000000001531] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 6.3] [Reference Citation Analysis]
7 Conway G, Velonias G, Andrews E, Garber JJ, Yajnik V, Ananthakrishnan AN. The impact of co-existing immune-mediated diseases on phenotype and outcomes in inflammatory bowel diseases. Aliment Pharmacol Ther 2017;45:814-23. [PMID: 28105709 DOI: 10.1111/apt.13940] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 4.2] [Reference Citation Analysis]